Michael Rodio | Oct. 31, 2013 | Harper Cancer Research Institute
Over the past 15 years, the scientific community has come to understand that breast cancer is a monster with many faces.
Some cancers have one of three special indicator molecules (HER2, estrogen receptors and progesterone receptors) that can guide targeted anti-cancer treatments. But another set of breast cancers, the “triple-negative” types, lack those three indicator molecules that can guide treatment. And even now, the question remains: How can doctors better target and treat triple-negative cancers? And how can they keep up the treatment when breast cancers fight back?
Here, in this poorly-mapped corner of breast cancer research, Dr. Jenifer Prosperi is trying to answer both questions by looking in one place.